Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study

Post time 7 day(s) ago

journal：Cardiovascular Research

Authors：Liwen Li; Yujie Zhou; Chanjuan Deng; Jianlong Sheng; Daoquan Peng; Zhiyu Ling; Luya Wang; Cuilian Dai; Kai Huang; Qiufang Lian; Zaixin Yu; Haibo Yang; Yuying Hu; YuGang Dong; Nan Wang; Zhen Wang; Wei Zhang; Xuebin Han; Zhuhua Yao; Qiyun Liu; Yingzi Liang; Biao Xu; Ying Wang; Tingyan Zhong; Jiyan Chen

Published date：2025-10-24

DOI：10.1093/cvr/cvaf155

PDF link：https://academic.oup.com/cardiov ... 4215658/cvaf155.pdf

Article link：https://doi.org/10.1093/cvr/cvaf155

Article Source：Oxford University Press (OUP)。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Oxford] Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Oxford] Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study Copy